KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Sarepta Therapeutics (SRPT) Profit After Tax (2016 - 2025)

Historic Profit After Tax for Sarepta Therapeutics (SRPT) over the last 14 years, with Q2 2025 value amounting to $196.9 million.

  • Sarepta Therapeutics' Profit After Tax rose 294786.38% to $196.9 million in Q2 2025 from the same period last year, while for Jun 2025 it was $396.0 million, marking a year-over-year increase of 73728.78%. This contributed to the annual value of $235.2 million for FY2024, which is 14388.98% up from last year.
  • According to the latest figures from Q2 2025, Sarepta Therapeutics' Profit After Tax is $196.9 million, which was up 294786.38% from $159.0 million recorded in Q4 2024.
  • In the past 5 years, Sarepta Therapeutics' Profit After Tax ranged from a high of $196.9 million in Q2 2025 and a low of -$516.8 million during Q1 2023
  • Moreover, its 5-year median value for Profit After Tax was -$48.1 million (2021), whereas its average is -$72.1 million.
  • Its Profit After Tax has fluctuated over the past 5 years, first tumbled by 85615.14% in 2021, then skyrocketed by 294786.38% in 2025.
  • Quarter analysis of 5 years shows Sarepta Therapeutics' Profit After Tax stood at -$122.0 million in 2021, then grew by 10.44% to -$109.2 million in 2022, then soared by 141.79% to $45.7 million in 2023, then skyrocketed by 248.37% to $159.0 million in 2024, then increased by 23.79% to $196.9 million in 2025.
  • Its last three reported values are $196.9 million in Q2 2025, $159.0 million for Q4 2024, and $33.6 million during Q3 2024.